Background: Many factors are believed to be positively associated with the incidence of relapses in people with multiple sclerosis (MS), including infections. However, their role is still controversial. We aimed to investigate whether symptomatic infections in people with MS increase the risk of relapse in the short, medium, or long term. Materials and Methods: We enrolled consecutive patients with relapsing MS (RMS) from October to December 2018. From enrolment up to September 2020, an online questionnaire investigating the occurrence of infections was sent via WhatsApp^® monthly to the enrolled patients, while in-person visits were performed every six months. When patients complained of symptoms compatible with relapses, they attended an extra in-person visit. Results: We enrolled 155 patients with RMS, and 88.38% of patients were treated with disease-modifying therapies. In the dataset, 126,381 total patient days, 78 relapses, and 1202 infections were recorded over a period of about 2 years. No increased risk of relapse after clinically manifest infections was found in the short-, medium-, or long-term period. No correlation was found between all infections and the number of relapses (p = 0.212). The main analyses were repeated considering only those infections that had at least two of the following characteristics: duration of infection ≥ 4 days, body temperature > 37° Celsius, and the use of drugs (antibiotics and/or antivirals), and no significant associations were observed. Conclusions: No associations between infections and relapses were observed, likely suggesting that disease-modifying therapies may protect against the risk of relapse potentially triggered by infections.

Background and Objectives: Brainstem infarctions remain challenging to identify due to their small size, complex anatomy, and known limitations of conventional axial diffusion-weighted imaging (DWI), particularly in the posterior fossa. Thin-section coronal DWI may improve lesion conspicuity by providing higher spatial resolution and an orthogonal imaging perspective. To evaluate whether 3 mm thin-section coronal DWI improves lesion visualization and delineation compared with standard 4 mm axial DWI in patients with MRI-confirmed acute brainstem infarction. Materials and Methods: In this retrospective single-center study, 125 consecutive patients with isolated brainstem infarction confirmed by MRI (January 2021–January 2024) were included. All patients underwent both axial and coronal DWI acquisitions. Lesions were classified by anatomical location and by the imaging plane providing better visualization (“coronal better” vs. “equal”). Lesion volumes were calculated using manual segmentation. Image interpretation was performed independently by two neuroradiologists. Interobserver agreement was assessed using Cohen’s kappa and intraclass correlation coefficient (ICC). Statistical analysis included both parametric and nonparametric tests, with confidence intervals reported. Results: Coronal DWI provided improved or equivalent lesion visualization in all cases. Improved visualization was most frequent in midbrain infarctions (100%) and in a subset of medullary lesions (26.7%). Lesions better visualized on coronal DWI were significantly smaller than those equally visualized (mean volume ~0.23 mL vs. ~0.55 mL, p < 0.0001). Twelve midbrain and eight medullary lesions were identified only on coronal DWI within the imaging protocol, all showing confirmation on ADC and/or FLAIR correlation. Interobserver agreement was substantial to excellent. Conclusions: Thin-section coronal DWI improves visualization and delineation of small brainstem infarctions, particularly in anatomically compact regions. These findings support its role as a complementary sequence rather than a replacement for standard axial imaging.